Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
NCT00570882
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
76
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG:
Sunitinib 2/1
DRUG:
Sunitinib 4/2
Sponsor
Asan Medical Center